Literature DB >> 19490286

Is surgery the next answer to treat obesity-related hypertension?

Eldo E Frezza1, Cai Wei, Mitchell S Wachtel.   

Abstract

Obesity is related to multiple comorbidities, including hypertension, diabetes, hypercholesterolemia, and sleep apnea. Comorbidities burden the health care system, such that in the United States, 6% to 8% of health care costs are related to obesity. Obesity-induced hypertension has multiple potential etiologic pathways, the most well established being increased renal sodium reabsorption with impaired pressure natriuresis via (1) activation of the renin-angiotensin system, (2) stimulation of the sympathetic nervous system, and (3) altered intrarenal physical forces. Weight loss is the best means to reduce obesity-related hypertension. For every 3 patients who lose 10 pounds of weight and maintain the weight loss for 4 years, 1 of them will eliminate the use of antihypertensive medication. Whereas nonsurgical therapy ineffectually treats extreme obesity, bariatric surgery yields durable weight loss, as well as resolution of some of the comorbidities associated with obesity, including hypertension. Increase in anti-inflammatory factors secreted by adipocytes may explain some of the improvement in blood pressure in the first 3 years post-procedure. Bariatric surgery safely and effectively improves and may improve or eliminate obesity-related hypertension. More data need to be collected to substantiate the same results over periods of time longer than 3 years.

Entities:  

Mesh:

Year:  2009        PMID: 19490286      PMCID: PMC8673382          DOI: 10.1111/j.1751-7176.2009.00123.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  51 in total

Review 1.  Obesity.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

2.  Laparoscopic Roux-en-Y gastric bypass for the treatment of morbid obesity: experience with 50 patients.

Authors:  Abed Khalaileh; Idit Matot; Chaya Schweiger; Liat Appelbaum; Ram Elazary; Andrei Keidar
Journal:  Isr Med Assoc J       Date:  2008-05       Impact factor: 0.892

3.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Gastric surgery for morbid obesity. The Adelaide Study.

Authors:  J C Hall; J M Watts; P E O'Brien; R E Dunstan; J F Walsh; A H Slavotinek; R G Elmslie
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

5.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

6.  Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients.

Authors:  Nicolas V Christou; John S Sampalis; Moishe Liberman; Didier Look; Stephane Auger; Alexander P H McLean; Lloyd D MacLean
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

7.  Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program.

Authors:  R Stamler; J Stamler; R Grimm; F C Gosch; P Elmer; A Dyer; R Berman; J Fishman; N Van Heel; J Civinelli
Journal:  JAMA       Date:  1987-03-20       Impact factor: 56.272

8.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.

Authors:  John B Dixon; Paul E O'Brien; Julie Playfair; Leon Chapman; Linda M Schachter; Stewart Skinner; Joseph Proietto; Michael Bailey; Margaret Anderson
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

9.  A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles.

Authors:  Teresa Mateo; Yafa Naim Abu Nabah; Mercedes Losada; Rossana Estellés; Chantal Company; Begoña Bedrina; Jose Miguel Cerdá-Nicolás; Stephen Poole; Peter J Jose; Julio Cortijo; Esteban J Morcillo; Maria-Jesus Sanz
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

10.  Vertical banded gastroplasty for the treatment of morbid obesity.

Authors:  S Ashley; D L Bird; G Sugden; C M Royston
Journal:  Br J Surg       Date:  1993-11       Impact factor: 6.939

View more
  5 in total

1.  Early and mid-term outcomes of single-stage laparoscopic sleeve gastrectomy.

Authors:  Sanket Srinivasa; Laura S Hill; Tarik Sammour; Andrew G Hill; Richard Babor; Habib Rahman
Journal:  Obes Surg       Date:  2010-11       Impact factor: 4.129

2.  Posterior reversible encephalopathy syndrome (PRES) after bariatric surgery--a potential consequence associated with rapid withdrawal of antihypertensive medications.

Authors:  Fatima Cody Stanford; Janey S Pratt; Ozanan R Meireles; Miriam A Bredella
Journal:  BMJ Case Rep       Date:  2015-12-23

3.  Medication Use Among Patients Prior to Bariatric Surgery.

Authors:  Jennifer Padden Elliott; Erica L Gray; Jessie Yu; Melissa A Kalarchian
Journal:  Bariatr Surg Pract Patient Care       Date:  2015-09-01       Impact factor: 0.607

4.  The Oxidative Stress Markers in the Erythrocytes and Heart Muscle of Obese Rats: Relate to a High-Fat Diet but Not to DJOS Bariatric Surgery.

Authors:  Bronisława Skrzep-Poloczek; Jakub Poloczek; Elżbieta Chełmecka; Agnieszka Dulska; Ewa Romuk; Maciej Idzik; Wojciech Kazura; Katarzyna Nabrdalik; Janusz Gumprecht; Jerzy Jochem; Dominika Marta Stygar
Journal:  Antioxidants (Basel)       Date:  2020-02-22

5.  Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity.

Authors:  Reza Aghamohammadzadeh; Adam S Greenstein; Rahul Yadav; Maria Jeziorska; Salam Hama; Fardad Soltani; Phil W Pemberton; Basil Ammori; Rayaz A Malik; Handrean Soran; Anthony M Heagerty
Journal:  J Am Coll Cardiol       Date:  2013-05-09       Impact factor: 24.094

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.